Exciting developments in Anti-VEGF therapy are afoot! 

Anti-VEGF is the gold standard for managing:

• Diabetic Macular Edema (DME)
• Wet Age-related Macular Degeneration (wet AMD)
• Retinal Vein Occlusion (RVO)

Blocking VEGF reduces retinal vascular leakage, improves visual acuity, and decreases macular thickness.

At the Congress, we will introduce BioUcenta — a high-quality, affordable biosimilar to Lucentis®, already approved in 22 countries with stringent FDA-like regulatory track records.

With BioUcenta, patients across Africa will have greater access to world-class sight-saving therapy—at a price that makes treatment sustainable and equitable.

Brought to you by Bio Usawa — a US- and Africa-based biotech company dedicated to delivering quality, affordable monoclonal antibodies for patients across Africa.

About Bio Usawa, Inc. (BUI)

Bio Usawa has a singular mission: to manufacture and commercialize high-quality, effective and affordable biosimilars for patients in Africa. We are applying our 100+ years of combined experience in the industry in partnership with governments, agencies, educators and health professionals to make transformative biomedicines in Africa, by Africans, for Africans and beyond. 

Click here to learn more about our company's recent successes and download our new White Paper on Regulatory Approaches to Biosimilars in Africa.